Renuvion® cleared by fda for neck laxity procedures offering patients a minimally invasive option to eliminate sagging neck

Exclusive apyx medical device delivers state-of-the-art plasma energy to improve appearance of loose skin on the neck and chin  available for physicians and patients clearwater, fla. , july 18, 2022 /prnewswire/ -- apyx medical corporation (nasdaq: apyx), the manufacturer of renuvion®, a proprietary helium plasma and radiofrequency technology, announces the receipt of 510(k) clearance from the u.s. food and drug administration ("fda") for the use of renuvion for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax skin in the neck and submental region.
APYX Ratings Summary
APYX Quant Ranking